Neuroprotective effects and mechanism of cognitive-enhancing choline analogs JWB 1-84-1 and JAY 2-22-33 in neuronal culture and Caenorhabditis elegans

Molecular Neurodegeneration

Volumn 5, Issue 1, 2010, Pages

  Keowkase, Roongpetch ^a,e   Aboukhatwa, Marwa ^a   Adam, Bao Ling ^b   Beach, J Warren ^c   Terry Jr , Alvin V ^b   Buccafussco, Jerry J ^b   Luo, Yuan ^a,d  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

^c UNIVERSITY OF GEORGIA   (United States)

^d UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^e SRINAKHARINWIROT UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; CHOLINE DERIVATIVE; JAY 2 22 33; JWB 1 84 1; NICOTINE DERIVATIVE; PRESENILIN 1; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN CELL; CAENORHABDITIS ELEGANS; CELL CULTURE; COGNITION; CONTROLLED STUDY; DRUG EFFECT; DRUG STRUCTURE; DRUG TARGETING; GENE MUTATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; NEUROPROTECTION; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RAT;

CAENORHABDITIS ELEGANS; MUS MUSCULUS; RATTUS;

EID: 78650102379     PISSN: None     EISSN: 17501326     Source Type: Journal    
DOI: 10.1186/1750-1326-5-59     Document Type: Article

References (52)

1. Pathways towards and away from Alzheimer's disease. MP Mattson, Nature 2004 430 7000 631 9 10.1038/nature02621 15295589
2. Alzheimer's disease. K Blennow MJ de Leon H Zetterberg, Lancet 2006 368 9533 387 403 10.1016/S0140-6736(06)69113-7 16876668
3. Alzheimer's disease. JL Cummings, N Engl J Med 2004 351 1 56 67 10.1056/NEJMra040223 15229308
4. Alzheimer's disease. HW Querfurth FM LaFerla, N Engl J Med 2010 362 4 329 44 10.1056/NEJMra0909142 20107219
5. Cognitive effects of nicotine. AH Rezvani ED Levin, Biol Psychiatry 2001 49 3 258 67 10.1016/S0006-3223(00)01094-5 11230877
6. Dissecting the signaling pathway of nicotine-mediated neuroprotection in a mouse Alzheimer disease model. Q Liu J Zhang H Zhu C Qin Q Chen B Zhao, FASEB J 2007 21 1 61 73 10.1096/fj.06-5841com 17135361
7. Chronic nicotine restores normal Abeta levels and prevents short-term memory and E-LTP impairment in Abeta rat model of Alzheimer's disease. M Srivareerat TT Tran S Salim AM Aleisa KA Alkadhi, Neurobiol Aging 2009 4 15
8. Nicotinic acetylcholine receptor signalling: roles in Alzheimer's disease and amyloid neuroprotection. SD Buckingham AK Jones LA Brown DB Sattelle, Pharmacol Rev 2009 61 1 39 61 10.1124/pr.108.000562 19293145
9. Loss of alpha7 nicotinic receptors enhances beta-amyloid oligomer accumulation, exacerbating early-stage cognitive decline and septohippocampal pathology in a mouse model of Alzheimer's disease. CM Hernandez R Kayed H Zheng JD Sweatt KT Dineley, J Neurosci 2010 30 7 2442 53 10.1523/JNEUROSCI.5038-09. 2010 20164328
10. An evaluation of neuronal nicotinic acetylcholine receptor activation by quaternary nitrogen compounds indicates that choline is selective for the alpha 7 subtype. RL Papke M Bencherif P Lippiello, Neurosci Lett 1996 213 3 201 4 8873149
11. Choline is a selective agonist of alpha7 nicotinic acetylcholine receptors in the rat brain neurons. M Alkondon EF Pereira WS Cortes A Maelicke EX Albuquerque, Eur J Neurosci 1997 9 12 2734 42 10.1111/j.1460-9568.1997. tb01702.x 9517478
12. Relative levels of cytoprotection produced by analogs of choline and the role of alpha7-nicotinic acetylcholine receptors. RR Jonnala JH Graham AV Terry Jr. JW Beach JA Young JJ Buccafusco, Synapse 2003 47 4 262 9 10.1002/syn.10176 12539199
13. Neuronal nicotinic receptor subtypes: defining therapeutic targets. JJ Buccafusco, Mol Interv 2004 4 5 285 95 10.1124/mi.4.5.8 15471911
14. The effects of JWB1-84-1 on memory-related task performance by amyloid Abeta transgenic mice and by young and aged monkeys. A Sood J Warren Beach SJ Webster AV Terry JJ Buccafusco, Neuropharmacology 2007 53 5 588 600 10.1016/j.neuropharm.2007.06.028 17698153
15. What have worm models told us about the mechanisms of neuronal dysfunction in human neurodegenerative diseases? D Teschendorf CD Link, Mol Neurodegener 2009 4 38 10.1186/1750-1326-4-38 19785750
16. Animal models of Alzheimer's disease and frontotemporal dementia. J Gotz LM Ittner, Nat Rev Neurosci 2008 9 7 532 44 10.1038/nrn2420 18568014
17. Dopaminergic neuronal loss and motor deficits in Caenorhabditis elegans overexpressing human alpha-synuclein. M Lakso S Vartiainen AM Moilanen J Sirvio JH Thomas R Nass RD Blakely G Wong, J Neurochem 2003 86 1 165 72 10.1046/j.1471-4159.2003.01809.x 12807436
18. Polyglutamine-mediated dysfunction and apoptotic death of a Caenorhabditis elegans sensory neuron. PW Faber JR Alter ME MacDonald AC Hart, Proc Natl Acad Sci USA 1999 96 1 179 84 10.1073/pnas.96.1.179 9874792
19. C. elegans models of age-associated neurodegenerative diseases: lessons from transgenic worm models of Alzheimer's disease. CD Link, Exp Gerontol 2006 41 10 1007 13 10.1016/j.exger.2006.06.059 16930903
20. The Caenorhabditis elegans A beta 1-42 model of Alzheimer disease predominantly expresses A beta 3-42. G McColl BR Roberts AP Gunn KA Perez DJ Tew CL Masters KJ Barnham RA Cherny AI Bush, J Biol Chem 2009 284 34 22697 702 10.1074/jbc.C109.028514 19574211
21. Opposing activities protect against age-onset proteotoxicity. E Cohen J Bieschke RM Perciavalle JW Kelly A Dillin, Science 2006 313 5793 1604 10 10.1126/science.1124646 16902091
22. Fluoxetine protects against amyloid-beta toxicity, in part via daf-16 mediated cell signaling pathway, in Caenorhabditis elegans. R Keowkase M Aboukhatwa Y Luo, Neuropharmacology 2010 59 4-5 358 65 10.1016/j.neuropharm. 2010.04.008 20420844
23. Current and future therapy in Alzheimer's disease. RJ van Marum, Fundam Clin Pharmacol 2008 22 3 265 74 10.1111/j.1472-8206.2008.00578.x 18485144
24. The insulin paradox: aging, proteotoxicity and neurodegeneration. E Cohen A Dillin, Nat Rev Neurosci 2008 9 10 759 67 10.1038/nrn2474 18769445
25. Worming pathways to and from DAF-16/FOXO. A Mukhopadhyay SW Oh HA Tissenbaum, Exp Gerontol 2006 41 10 928 34 10.1016/j.exger.2006.05.020 16839734
26. The search for DAF-16/FOXO transcriptional targets: approaches and discoveries. CT Murphy, Exp Gerontol 2006 41 10 910 21 10.1016/j.exger.2006.06. 040 16934425
27. Recent aging research in Caenorhabditis elegans. E Schaffitzel M Hertweck, Exp Gerontol 2006 41 6 557 63 10.1016/j.exger.2006.02.008 16584861
28. Inhibition of amyloid-beta aggregation and caspase-3 activation by the Ginkgo biloba extract EGb761. Y Luo JV Smith V Paramasivam A Burdick KJ Curry JP Buford I Khan WJ Netzer H Xu P Butko, Proc Natl Acad Sci USA 2002 99 19 12197 202 10.1073/pnas.182425199 12213959
29. Nicotinic receptor agonists and antagonists increase sAPPalpha secretion and decrease Abeta levels in vitro. M Mousavi E Hellstrom-Lindahl, Neurochem Int 2009 54 3-4 237 44 10.1016/j.neuint.2008.12.001 19111588
30. Guidelines on nicotine dose selection for in vivo research. SG Matta DJ Balfour NL Benowitz RT Boyd JJ Buccafusco AR Caggiula CR Craig AC Collins MI Damaj EC Donny PS Gardiner SR Grady U Heberlein SS Leonard ED Levin RJ Lukas A Markou MJ Marks SE McCallum N Parameswaran KA Perkins MR Picciotto M Quik JE Rose A Rothenfluh WR Schafer IP Stolerman RF Tyndale JM Wehner JM Zirger, Psychopharmacology (Berl) 2007 190 3 269 319 10.1007/s00213-006-0441-0 16896961
31. Chronic transdermal nicotine patch treatment effects on cognitive performance in age-associated memory impairment. HK White ED Levin, Psychopharmacology (Berl) 2004 171 4 465 71 10.1007/s00213-003-1614-8 14534771
32. Absence of effect of chronic nicotine administration on amyloid beta peptide levels in transgenic mice overexpressing mutated human APP (Sw, Ind). MN Sabbagh DG Walker RT Reid T Stadnick K Anand LF Lue, Neurosci Lett 2008 448 2 217 20 18926877
33. Finding function in novel targets: C. elegans as a model organism. T Kaletta MO Hengartner, Nat Rev Drug Discov 2006 5 5 387 98 10.1038/nrd2031 16672925
34. Insulin signaling in sporadic Alzheimer's disease. FF Liao H Xu, Sci Signal 2009 2 74 e36 10.1126/scisignal.274pe36 19509405
35. Soluble Abeta inhibits specific signal transduction cascades common to the insulin receptor pathway. M Townsend T Mehta DJ Selkoe, J Biol Chem 2007 282 46 33305 12 10.1074/jbc.M610390200 17855343
36. Insulin receptor dysfunction impairs cellular clearance of neurotoxic oligomeric a{beta}. WQ Zhao PN Lacor H Chen MP Lambert MJ Quon GA Krafft WL Klein, J Biol Chem 2009 284 28 18742 53 10.1074/jbc.M109.011015 19406747
37. The model Caenorhabditis elegans in diabetes mellitus and Alzheimer's disease. M Morcos H Hutter, J Alzheimers Dis 2009 16 4 897 908 19387121
38. Regulation of aging and age-related disease by DAF-16 and heat-shock factor. AL Hsu CT Murphy C Kenyon, Science 2003 300 5622 1142 5 10.1126/science.1083701 12750521
39. Regulation of longevity in Caenorhabditis elegans by heat shock factor and molecular chaperones. JF Morley RI Morimoto, Mol Biol Cell 2004 15 2 657 64 10.1091/mbc.E03-07-0532 14668486
40. Dietary restriction suppresses proteotoxicity and enhances longevity by an hsf-1-dependent mechanism in Caenorhabditis elegans. KA Steinkraus ED Smith C Davis D Carr WR Pendergrass GL Sutphin BK Kennedy M Kaeberlein, Aging Cell 2008 7 3 394 404 10.1111/j.1474-9726.2008.00385.x 18331616
41. acr-16 encodes an essential subunit of the levamisole-resistant nicotinic receptor at the Caenorhabditis elegans neuromuscular junction. D Touroutine RM Fox SE Von Stetina A Burdina DM Miller JE Richmond, J Biol Chem 2005 280 29 27013 21 10.1074/jbc.M502818200 15917232
42. Nicotinic acetylcholine receptors in the nematode Caenorhabditis elegans. M Ballivet C Alliod S Bertrand D Bertrand, J Mol Biol 1996 258 2 261 9 10.1006/jmbi.1996.0248 8627624
43. Caenorhabditis elegans levamisole resistance genes lev-1, unc-29, and unc-38 encode functional nicotinic acetylcholine receptor subunits. JT Fleming MD Squire TM Barnes C Tornoe K Matsuda J Ahnn A Fire JE Sulston EA Barnard DB Sattelle JA Lewis, J Neurosci 1997 17 15 5843 57 9221782
44. A C. elegans mutant that lives twice as long as wild type. C Kenyon J Chang E Gensch A Rudner R Tabtiang, Nature 1993 366 6454 461 4 10.1038/366461a0 8247153
45. A mutant Drosophila insulin receptor homolog that extends life-span and impairs neuroendocrine function. M Tatar A Kopelman D Epstein MP Tu CM Yin RS Garofalo, Science 2001 292 5514 107 10 10.1126/science.1057987 11292875
46. IGF-1 receptor regulates lifespan and resistance to oxidative stress in mice. M Holzenberger J Dupont B Ducos P Leneuve A Geloen PC Even P Cervera Y Le Bouc, Nature 2003 421 6919 182 7 10.1038/nature01298 12483226
47. Association of FOXO3A variation with human longevity confirmed in German centenarians. F Flachsbart A Caliebe R Kleindorp H Blanche H von Eller-Eberstein S Nikolaus S Schreiber A Nebel, Proc Natl Acad Sci USA 2009 106 8 2700 5 10.1073/pnas.0809594106 19196970
48. FOXO3A genotype is strongly associated with human longevity. BJ Willcox TA Donlon Q He R Chen JS Grove K Yano KH Masaki DC Willcox B Rodriguez JD Curb, Proc Natl Acad Sci USA 2008 105 37 13987 92 10.1073/pnas.0801030105 18765803
49. Functionally significant insulin-like growth factor I receptor mutations in centenarians. Y Suh G Atzmon MO Cho D Hwang B Liu DJ Leahy N Barzilai P Cohen, Proc Natl Acad Sci USA 2008 105 9 3438 42 10.1073/pnas.0705467105 18316725
50. Analogs of choline for neuroprotection and cognitive enhancement in neurodegenerative disorders. JJ Buccafusco JW Beach AV Terry RR Jonnala, Patent Number: 6,881,738; issue date: 04/19/05
51. Metabolism of the "Swedish" amyloid precursor protein variant in neuro2a (N2a) cells. Evidence that cleavage at the "beta-secretase" site occurs in the golgi apparatus. G Thinakaran DB Teplow R Siman B Greenberg SS Sisodia, J Biol Chem 1996 271 16 9390 7 10.1074/jbc.271.16.9390 8621605
52. Expression of human beta-amyloid peptide in transgenic Caenorhabditis elegans. CD Link, Proc Natl Acad Sci USA 1995 92 20 9368 72 10.1073/pnas.92.20. 9368 7568134